{"slug":"radiation-wave3","tag":"radiation-wave3","variants":["radiation-wave3"],"description":"No description yet","count":6,"kinds":{"drug":5,"company":1},"related":[{"slug":"radiation","tag":"radiation","shared":1}],"records":[{"id":"nimorazole","kind":"drug","name":"Nimorazole","route":"/drugs/nimorazole/","status":"established","tldr":"Nimorazole is the one hypoxic radiosensitiser in routine use: given with radiotherapy for head and neck cancer in Denmark since the DAHANCA 5 trial improved control, and tested across Europe in patients whose tumours carry a hypoxia gene signature."},{"id":"nbtxr3","kind":"drug","name":"NBTXR3 (hafnium oxide nanoparticles)","route":"/drugs/nbtxr3/","status":"phase-3","tldr":"NBTXR3 is Nanobiotix's radioenhancer: a single injection of hafnium oxide nanoparticles that makes ordinary radiotherapy hit harder inside the tumour. It carries a European CE mark for soft-tissue sarcoma and is in a phase 3 trial in head and neck cancer with Johnson and Johnson."},{"id":"pilocarpine","kind":"drug","name":"Pilocarpine","route":"/drugs/pilocarpine/","status":"approved","tldr":"Pilocarpine tablets are approved to treat the dry mouth that follows head and neck radiotherapy; they help when some gland tissue is left, at the cost of sweating and other cholinergic side effects."},{"id":"avasopasem-manganese","kind":"drug","name":"Avasopasem manganese","route":"/drugs/avasopasem-manganese/","status":"phase-3","tldr":"Avasopasem is Galera Therapeutics' radioprotector for the severe mouth ulcers of head and neck chemoradiation; its phase 3 trial met its main goal but the FDA asked for another study in 2023."},{"id":"evofosfamide","kind":"drug","name":"Evofosfamide","route":"/drugs/evofosfamide/","status":"negative","tldr":"Evofosfamide was the most advanced hypoxia-activated drug, designed to kill the oxygen-starved tumour cells radiotherapy and chemotherapy miss, but it failed both of its phase 3 trials in 2015."},{"id":"nanobiotix","kind":"company","name":"Nanobiotix","route":"/companies/nanobiotix/","tldr":"Nanobiotix is the Paris nanomedicine company behind NBTXR3, hafnium oxide nanoparticles injected into a tumour to make radiotherapy deposit more energy inside it."}]}